Diagnostic Center | June 01, 2024
Sun Pharma to present results of the Phase III PIVOTAL trial of Nidlegy in melanoma at ASCO 2024
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy